MedCity Influencers

Trading the Blackberry for an iPhone (Best of MedCitizens)

Every week, MedCity News highlights the best of its MedCitizens: syndication partners and MedCity news readers who discuss life science current events on MedCityNews.com. Now here’s the best of what YOU had to say.

Every week, MedCity News highlights the best of its MedCitizens: syndication partners and MedCity news readers who discuss life science current events on MedCityNews.com.

Now here’s the best of what YOU had to say:

When a CIO switches from a Blackberry to an iPhone. “My switch to an iPhone 4S was predicated on a need to communicate with more flexibility, power, and speed than a Blackberry could support.”

Autism-vaccine link challenged by new info on brains of autistic children.  “A recent study published in the Journal of the American Medical Association, however, sheds new light on physiological roots — though not causes — of autism [2], and in so doing rules out the potential for any link between vaccination and development of the disease.”

Choosing the best startup funding for your business. “As 2011 winds down, small business owners looking for new financing options would do well to take a slice of the holidays and use it to study the two most common startup funding options — angel investing versus venture capital.”

HIPPA compliant yet disclosing patient information? It may happen (in unique cases). “But doctors should not be afraid of publishing case reports especially since there are good reasons for them clinically. Further, when doctors make good faith efforts to conceal patient’s personal information in those reports, they should not be subject to threats of HIPAA’s ‘small cell’ problem.”

FDA’s Avastin breast cancer decision was just right. “The drug will remain on the market for other cancer indications, so if a physician wants to prescribe it for breast cancer they can. However, some patients may have a hard time getting reimbursement from their commercial health plan. Not everyone will have this problem, though, because Medicare and some health plans (including United) will continue to reimburse as long as the drug is listed as appropriate for breast cancer by the National Comprehensive Cancer Network (NCCN).”

This post appears through the MedCity Influencers program. Anyone can publish their perspective on business and innovation in healthcare on MedCity News through MedCity Influencers. Click here to find out how.